Brivudine is an antiviral drug acts by inhibiting replication of the target virus, used in the treatment of Herpes Zoster.

CC-115 is an inhibitor of mTOR and DNA-PK with IC50 of 21 and 13 nM respectively.

PIK-75 is a selective p110α inhibitor with IC50 of 5.8 nM with 200-fold more potently than p110β, and also potently inhibits DNA-PK with IC50 of 2 nM.

NU7441 is a potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.

DNA-PK-IN-8是一种高效且具有选择性和口服活性的 DNA 依赖蛋白激酶 (DNA-PK) 抑制剂，IC₅₀ 为 0.8 nM。与 Doxorubicin 联合使用时，该化合物在多种癌症模型中展现出协同抗增殖作用，并显著抑制肿瘤生长，特别是在 HL-60 肿瘤模型中。

VX-984是一种口服有效的选择性 DNA-PK 抑制剂，可透过血脑屏障，有效抑制非同源末端接合 (NHEJ)，增加 DNA 双链断裂 (DSBs)，用于胶质母细胞瘤 (GBM) 和非小细胞肺癌 (NSCLC) 的研究，属于从头设计的氘代物。

AZD7648 is a highly potent and selective DNA-PK inhibitor with IC50 value of 92nM.

M-3814, also known as MSC2490484A and nedisertib, is an orally available inhibitor of DNA-dependent protein kinase (DNA-PK), with potential antineoplastic and chemo/radiosensitizing activities.

IC 86621是一种高效的 DNA 依赖蛋白激酶 (DNA-PK) 抑制剂，IC₅₀ 为 120 nM。该化合物还能够抑制 DNA 双链断裂修复，增强抗肿瘤活性，且无明显的细胞毒性作用。

Wortmannin（SL-2052；KY-12420）是一种有效、选择性和不可逆的PI3K抑制剂，IC50为3 nM。它还阻止自噬形成，强效抑制Polo样激酶1（PlK1）和Plk3的IC50分别为5.8 nM和48 nM。

PIK-75 is a selective p110α inhibitor with IC50 of 5.8 nM with 200-fold more potently than p110β, and also potently inhibits DNA-PK with IC50 of 2 nM.

LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK with an IC50 of 64.9 nM, 42.1 nM, 10.6 nM, 19.1 nM for Akt1 (pT308), Akt1 (pS473), P70S6 (pT389), S6RP (pS240/242).

PI-103 is a potent inhibitor with low IC50 values against recombinant PI3K isoforms p110alpha (IC50= 2 nM), p110beta (IC50= 3 nM), p110delta (IC50= 3 nM), and p110gamma (IC50= 15 nM), less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM. It blocks autophagic flux.

NU7026 is a potent and selective inhibitor of DNA-PK with IC50 of 0.23 μM.

DMNB is a volatile organic compound used as a detection taggant for explosives.

(Rac)-Nedisertib是一种小分子CDK抑制剂，通过调节细胞周期和增殖来研究其在癌症治疗中的作用。